NEW
YORK, Jan. 30, 2025 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or
the "Company"), a leader in microwave ablation (MWA) technology,
today announced its successful participation in the 2025 Microcap
Conference, held at the Borgata Hotel in Atlantic City, New Jersey. The Company
showcased its innovative solutions and engaged in high-level
discussions with investors and industry leaders during the 3-day
event.
As the largest independent microcap conference in the U.S., the
2025 Microcap Conference brought together over 750 institutional
investors, venture capital representatives, and industry experts
from around the world. This prestigious event provided Baird
Medical with an exceptional platform to highlight its technological
advancements and explore strategic opportunities.
At the conference, Baird Medical demonstrated its cutting-edge
minimally invasive microwave ablation technology, drawing
significant attention from attendees and underscoring the Company's
leadership in research and development. Additionally, the Company
shared its global expansion strategy following the recent FDA
510(k) clearance for the U.S. market.
During the event, Baird Medical's leadership team held numerous
one-on-one meetings with investors, detailing the Company's growth
plans for the U.S. market, including market penetration strategies
and product promotion initiatives. The team also engaged in
extensive discussions with several industry players regarding
potential mergers and acquisitions. These conversations focused on
resource integration, technological synergies, and market
collaboration, aiming to identify strategic opportunities that
could drive mutual growth and advance the microwave ablation
industry.
"The Microcap Conference provided us with a valuable opportunity
to connect with global investors and industry partners," said
Haimei Wu, Chairwoman of Baird Medical. "We not only showcased our
technological expertise but also gained clarity on future
collaboration opportunities. We look forward to accelerating our
global market expansion and achieving efficient resource
integration through strategic mergers and acquisitions."
Moving forward, Baird Medical plans to leverage the insights and
partnerships gained from the conference to further its mission of
improving patient outcomes worldwide through innovative
technologies. The Company will continue to invest in research and
development to enhance product quality and performance while
actively exploring merger and acquisition opportunities to
consolidate its global leadership in the microwave ablation field.
By integrating complementary resources, Baird Medical aims to
deliver superior medical solutions to patients around the
world.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave
ablation (MWA) technology, offering advanced treatment solutions
for conditions such as thyroid nodules, breast disease, uterine
fibroids, and liver cancer. A publicly traded company on NASDAQ,
Baird Medical is dedicated to enhancing patient care through
precision, efficiency, and safety in its innovative medical
devices. For more information, please visit
https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts and generally relate to future events or
Baird Medical's future financial or operational performance. In
some cases, you can identify forward-looking statements by
terminology such as "may," "might," "will," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," or the negative of these terms or other
similar expressions.
These forward-looking statements are subject to risks,
uncertainties, and assumptions that could cause actual results or
outcomes to differ materially from those expressed or implied.
These statements are based on estimates and assumptions that, while
considered reasonable by Baird Medical and its management, are
inherently uncertain. Risks and uncertainties may emerge over time,
and it is not possible to anticipate all potential factors that
could affect Baird Medical's business and financial
performance.
Factors that could cause actual results to differ materially
include, but are not limited to: (1) the risk that Baird Medical
may not achieve its expansion goals in the United States, China, or other markets; (2) changes in
economic, regulatory, or market conditions that impact Baird
Medical's operations; (3) the ability to realize anticipated
benefits from ongoing business initiatives or strategic
transactions; (4) regulatory developments and compliance with
applicable laws; (5) risks related to the development,
commercialization, and market acceptance of Baird Medical's
products; and (6) other risks and uncertainties detailed in Baird
Medical's filings with the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Baird Medical undertakes no obligation to update or
revise forward-looking statements, whether as a result of new
information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-shines-at-2025-microcap-conference-driving-growth-through-technological-innovation-and-strategic-collaborations-302363962.html
SOURCE BDMD
